Nabil Ismaili, Director of Medical Oncology and Radiotherapy Department at Mohammed VI University of Sciences and Health, shared on LinkedIn:
“Excited to be in Madrid for ESMO 2026!
As we dive into the latest breakthroughs, I wanted to share a fantastic summary of the Major Studies to Watch from the conference.
These trials are pushing the boundaries across multiple tumor types and therapeutic strategies:
Cancer Vaccines:
INterpath-001: Can individualized mRNA neoantigens help prevent melanoma relapse? A fascinating frontier in precision immunotherapy.
KRAS Directed:
KRASCENDO-1: Will a head-to-head trial raise the standard for KRAS G12C NSCLC? Moving beyond single-arm data.
Drug Resistance:
SAFFRON: Can EGFR/MET biomarker selection overcome acquired resistance? A crucial step for optimizing targeted therapy sequences.
Biliary Tract Cancer:
HARMONI-GI1: Can a PD-1/VEGF bispecific improve first-line BTC care? Potentially establishing a new standard.
Antibody-Drug Conjugates (ADCs):
TroFuse-005: What role will novel ADCs have in recurrent endometrial cancer? The ADC revolution continues to expand.
Perioperative Therapy:
VOLGA: Can an ADC-immunotherapy strategy improve bladder cancer care? Redefining the neoadjuvant/perioperative space.
Gastroesophageal Cancer:
CLARITY-Gastric 01: How far can CLDN18.2-directed treatment extend? A highly anticipated update for GI oncology.
These data sets highlight the incredible shift towards bispecifics, next-gen ADCs, and personalized vaccine strategies.”
Other articles about ESMO 2026 on OncoDaily.